#China #Shanghai #Fosun Pharma #Han Si Zhuang #Innovative Drugs

Fosun Pharma's 2024 Annual Results: A Year of Growth and Innovation

On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., widely referred to as Fosun Pharma, announced its annual results for the year ending December 31, 2024. This leading global pharmaceutical and healthcare company, with a stock code of 600196.SH and 02196.HK, reported a substantial increase in operating revenue and net profit, further solidifying its position in the market.

In 2024, Fosun Pharma achieved an impressive operating revenue of RMB 41.07 billion, reflecting a growth of 16.08% compared to the previous year. Notably, the net profit attributable to shareholders totaled RMB 2.77 billion. One of the standout achievements for the year was the surge in operating cash flow, which exceeded expectations with a growth of 31.13%, bringing in RMB 4.48 billion. This remarkable cash flow growth showcases the company’s strengthening operational efficiency driven by optimized supply chain management.

Fosun Pharma aims to push the envelope on innovation as a primary driver of its long-term success. The company has created a globally integrated R&D ecosystem, emphasizing key therapeutic areas like oncology—particularly solid tumors and hematologic malignancies—and immune-inflammatory disorders. Their focus on cutting-edge technologies includes advancements in antibody and ADC platforms, cellular therapies, and small molecule development.

During the year, Fosun Pharma's commitment to R&D remained firm, with total expenditures reaching RMB 5.55 billion. The company lodged over 220 patent applications, leading innovations in drug formulations that will likely redefine treatment protocols in several areas of medicine, including rare diseases.

Accelerating Innovation and International Expansion

Fosun Pharma has placed considerable focus on addressing unmet clinical needs by advancing its product pipeline and introducing innovative treatments to international markets. Throughout 2024, the company successfully launched seven innovative drugs/biosimilars with a total of 16 indications. Eight additional products reached critical clinical trial stages, showcasing Fosun Pharma's dedication to transforming patient care.

Significantly, during this period, Fosun Pharma introduced Han Si Zhuang (Serplulimab Injection), an anti-PD-1 monoclonal antibody that has transformed treatment options for lung cancer. This groundbreaking therapy is the first of its kind approved for extensive-stage small cell lung cancer in multiple regions, including the EU and China, benefiting over 100,000 patients worldwide.

In addition to their achievements in lung cancer treatment, Fosun Pharma has expanded its innovative product offerings in high-incidence cancers such as breast and gastric cancers. Their biosimilar Han Qu You, targeting HER2, is now available in over 50 countries, signifying a significant step towards global accessibility.

The company's efforts are not limited to oncology; they are actively pursuing therapies for rare diseases, with promising developments such as Luvometinib addresses complex tumor types and genetic conditions in children.

Expanding Global Operations

Fosun Pharma's international revenue reached RMB 11.30 billion in 2024, making up 27.51% of their total revenue, as the organization benefits from its internationalized strategy in innovative research, licensing, manufacturing, and commercialization. Significant strides have been made toward building production capabilities that align with international standards, paving the way for the distribution of high-quality products across major regulatory markets.

The in-house generic drug team in the U.S. has seen steady growth, with Fosun Pharma developing partnerships with major distributors, while their European subsidiary has bolstered localized manufacturing capabilities.

Furthermore, the company is strengthening partnerships in emerging markets, including Africa and the Middle East, broadening its reach and ensuring tailored healthcare solutions for diverse populations.

Commitment to Innovation and Social Responsibility

Wu Yifang, Chairman of Fosun Pharma, reaffirmed the company's commitment to pursuing innovation-driven strategies, emphasizing the imperative of a patient-centric approach in healthcare. The outstanding milestones achieved in 2024 underline Fosun Pharma’s dedication to addressing pressing medical needs, fostering innovation, and elevating global health standards. Fosun Pharma remains resolute in its mission to create better health for families globally, combining healthcare integration with innovative research and responsive operational practices.

In its pursuit of excellence, Fosun Pharma also champions sustainable practices and social responsibility, earning recognition both locally and internationally for its ESG progress and continued commitment to corporate responsibility. As they look to the future, Fosun Pharma is poised to continue leading advancements in cross-border health solutions, fostering innovation, and creating a meaningful impact in the pharmaceutical landscape.